ESSA Pharma Inc EPIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if EPIX is a good fit for your portfolio.
News
-
ESSA Pharma to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
-
ESSA PHARMA INC. REPORTS RESULTS OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
-
Thinking about buying stock in Adverum Biotechnologies, Roma Green Finance, Wah Fu Education, ESSA Pharma, or Science 37?
-
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal First Quarter Ended December 31, 2023
-
ESSA Pharma to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
-
Thinking about trading options or stock in General Electric, Taiwan Semiconductor, Shopify, ESSA Pharma, or Snap?
Trading Information
- Previous Close Price
- $6.12
- Day Range
- $5.71–6.22
- 52-Week Range
- $2.56–11.67
- Bid/Ask
- $5.67 / $5.95
- Market Cap
- $255.11 Mil
- Volume/Avg
- 53,793 / 124,996
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 50
- Website
- https://www.essapharma.com
Comparables
Valuation
|
Metric
|
EPIX
|
NYKD
|
FUSN
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.96 | 2.42 | 7.67 |
Price/Sales | — | 28.37 | 678.96 |
Price/Cash Flow | — | — | — |
Price/Earnings
EPIX
NYKD
FUSN
Financial Strength
|
Metric
|
EPIX
|
NYKD
|
FUSN
|
|---|---|---|---|
Quick Ratio | 40.30 | 7.91 | 14.66 |
Current Ratio | 40.75 | 8.04 | 15.01 |
Interest Coverage | −6,585.38 | −235.75 | −19.06 |
Quick Ratio
EPIX
NYKD
FUSN
Profitability
|
Metric
|
EPIX
|
NYKD
|
FUSN
|
|---|---|---|---|
Return on Assets (Normalized) | −14.71% | −19.18% | −33.14% |
Return on Equity (Normalized) | −15.02% | −26.31% | −43.87% |
Return on Invested Capital (Normalized) | −17.17% | −30.96% | −36.42% |
Return on Assets
EPIX
NYKD
FUSN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Drqkfrhpn | Ngtx | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kcqmbhwvq | Jklpgd | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Vkzkwfyp | Wrcvjc | $97.8 Bil | |
MRNA
| Moderna Inc | Ymfsfpk | Hftr | $38.8 Bil | |
ARGX
| argenx SE ADR | Gvfvmqfrs | Wjnj | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Mbhdlbwyh | Fdcm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Scghnbg | Fszkvqf | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xfqdzbcz | Rlwpkvy | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gsbrxysdzh | Txlncxm | $12.5 Bil | |
INCY
| Incyte Corp | Kncvbmh | Zgvkdb | $11.5 Bil |